EMA Cracks Down on Noncompliant Trials

Drug Industry Daily
A A
The European Medicines Agency is moving to reject substitute proof-of-concept trials in place of GCP noncompliant studies during marketing application reviews.

To View This Article:

Login

Subscribe To Drug Industry Daily